Systemic and biophase bioavailability and pharmacokinetics of nanoparticulate drug delivery systems

Current Drug Delivery

Volumn 10, Issue 2, 2013, Pages 208-240

  Leucuta, Sorin Emilian ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Bioavailability; Drug delivery systems; Internalization; Intracellular; Intranuclear; Nanoparticles; Pharmacokinetics; Targeting

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANGIOPEPTIN; ANTISENSE OLIGONUCLEOTIDE; ASPARAGINASE MACROGOL; BIOSIMILAR AGENT; DOXORUBICIN; EPIRUBICIN; IMMUNOMODULATING AGENT; INSULIN; LURTOTECAN; MONOCLONAL ANTIBODY; NANOCARRIER; NAVELBINE; NYSTATIN; OCTREOTIDE; PACLITAXEL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RISPERIDONE; SMALL INTERFERING RNA; TRASTUZUMAB; VAPREOTIDE; VINCRISTINE; VIVAGEL;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CANCER GENE THERAPY; CHEMOEMBOLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DRUG TARGETING; HUMAN; INTERNALIZATION; LIPOSOMAL DELIVERY; MAXIMUM PLASMA CONCENTRATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PHAGOCYTOSIS; PHARMACOKINETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHARMACOKINETICS;

EID: 84876875294     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201811310020007     Document Type: Article

References (246)

1. Caruthers, S.D.; Wickline, S.A.; Lanza, G.M. Nanotechnological applications in medicine. Curr. Opin. Biotechnol., 2007, 18, 26-30.
2. Saja, H.K.; East, M.P.; Mao, H.; Wang, A.Y.; Nie, S.; Yang, L. Development of multifunctional nanoparticles for targeted drug delivery and non-invasive imaging of therapeutic effect. Curr. Drug Discov. Technol., 2009, 6, 43-51.
3. Sahoo, S.K.; Parveen, S.; Panda, J.J. The present and future of nanotechnology in human health care. Nanomed. Nanotechnol., Biol. Med., 2007, 3, 20-31.
4. Jain, K.K. Nanotechnology in clinical laboratory diagnostics. Clin. Chim. Acta, 2005, 358, 37-54.
5. Leucuta, S.E. Nanotechnology for delivery of drugs and biomedical applications. Curr. Clin. Pharmacol., 2010, 5, 257-280.
6. Hernandez, M.A.; Rathinavelu, A. Basic Pharmacology: Understanding Drug Actions and Reaction; CRC Press; 2006.
7. th Ed; Lippincott Williams&Wilkins, Wolters Kluwer:Baltimore, Philadelphia, 2011.
8. Wagner, J.G. History of pharmacokinetics. Pharmac. Ther., 1981, 12, 537-562.
9. Krishna, R.; Yu L. Biopharmaceutics Applications in Drug Development; Springer, 2008.
10. Notari, RE. Biopharmaceutics and pharmacokinetics: an introduction; M. Dekker: New York, 1971.
11. Leucuta, S.E. Introduction to Biopharmaceutics (in Romanian); Editura Dacia: Cluj-Napoca, 1975.
12. Gibaldi, M.; Perrier, D. Pharmacokinetics, 2nd Ed.; M. Dekker: New York, 1982.
13. Leucuta, S.E.; Pop, R.D. Pharmacokinetics (in Romanian); Editura Dacia: Cluj-Napoca, 1981.
14. Benet, L.Z. Pharmacokinetics: Basic principles and its use as a tool in drug metabolism. In: Drug Metabolism and Drug Toxicity, J.R. Mitchell and MG. Horning (Eds.), Raven Press: New York, 1984.
15. Turner, J.R. New Drug Development. An introduction to clinical trials. 2nd Ed; Springer, 2010.
16. Brunton, L.L. Chabner, B.A.; Knollmann, B.C. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e; McGraw Hill, 2006.
17. U.S. Food and Drug Agency, CFR-Code of Federal Regulations Title 21 Part 320 Bioavailability and bioequivalence requirements, 2011.
18. The European Agency for the Evaluation of Medicinal Products, CPMP/EWP/QWP/1401/98 Note for Guidance on the Investigation of bioavailability and bioequivalence, London, 2000.
19. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, March 2003, http://www.fda.gov/cder/guidance/index.htm
20. European Medicines Agency, CPMP/EWP/QWP/1401/98 Rev. 1, Guideline on the investigation of bioequivalence, London 2010, http://www.ema.europa.eu
21. Thiessen, J.J. In The IUPHAR Compendium of Basic Principles for Pharmacological Research in Humans; P. du Souich, M. Orme and S. Erill, Ed's, IUPHAR, Chp. 8: Bioavailability and Bioequivalence, 2004, 55-66.
22. Kanfer, I.; Shargel, L. (Eds.). Generic drug product development: bioequivalence issues; Informa Healthcare: New York, 2010.
23. Cheng, H.J.; Codamo, J.; Pilbrough. W.; Hughes, B.; Gray, P.P.; Munro, T.P. New frontiers in cell line development: challenges for biosimilars. J. Chem. Tech. Biotechnol., 2011, 86(7), 895-904.
24. Chiellini, E.; Sunamoto, J.; Migliaresi, C.; Ottenbrite, R.M.; Cohn D. Biomedical Polymers and Polymer Therapeuuics, Kluwer Academic Pub.: New York, 2002.
25. Lalonde, R.L.; Honig, P. Clinical Pharmacology in the era of biotherapeutics. Clin. Pharmacol. Therap., 2008, 84, 533-536.
26. World Health Organization, Guidelines on evaluation of similar biotherapeutic products (SBPs), Geneve, 2009.
27. Danhof, M.; Mandema, J.W.; Hoogerkamp, A; Mathot, R.A.A. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Eur. J. Drug Metab. Pharmacokin., 1993, 18, 41-47.
28. Weigand, W.A.; Jhawar, A.K. Dose-effect curves and relative biophasic drug levels: Elucidation of these concepts and the illustration of their use for the determination of bioavailability, rate of absorption, and time course of pharmacological response. J. Pharmacokin. Pharmacodyn., 1976, 4, 67-80.
29. Sahoo, S.K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov Today, 2003, 8,1112-20.
30. Saini, R.; Saini, S.; Sharma S. Nanotechnology: The Future Medicine. J. Cutan. Aesthet. Surg., 2010, 3,32-33.
31. Petrak, K. Essential properties of drug targeting delivery systems. Drug Discov. Today, 2005, 20, 1667-1673.
32. Kubik, T.; Bogunia-Kubik, K.; Sugisaka, M. Nanotechnology on duty in medical applications. Curr. Pharm. Biotechnol., 2005, 6, 17-33.
33. Kayser, O.; Lemke, A.; Hernandez-Trejo, N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol., 2005, 6, 3-5.
34. Danhof, M.; De Jongh, J.; De Lange, E.C.M.; Della Pasqua, O.; Ploweger, B.A.; Voskuyl, R.A. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Ann. Rev. Pharmacol. Toxicol., 2007, 47, 357-400.
35. Sahoo, S.K.; Parveen, S.; Panda, J.J. The present and future of nanotechnology in human health care. Nanomedicine: Nanotechnol. Biol. Med., 2007, 3, 20-31.
36. El-Shabouri, M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm., 2002, 249, 101-8.
37. Hu, L.; Tang, X.; Cui, F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J. Pharm. Pharmacol., 2004, 56, 1527-1535.
38. Arangoa, M.A.; Campanero, M.A.; Renedo, M.J.; Ponchel, G.; Irache, J.M. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm. Res., 2001, 18, 1521-1527.
39. Arbos, P.; Campanero, M.A.; Arangoa, M.A.; Irache J.M. Nanoparticles with specific bioadhesive properties to circumvent the presystemic degradation of fluorinated pyrimidines. J. Control. Release, 2004, 96, 55-65.
40. Evans, W. E.; Schentag, J. J.; Jusko, W. J.; Harrison, H.; Eds, In: Evans, W. E.; Schentag, J. J., Eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd Ed, Applied Therapeutics: Vancouver, 1992.
41. Bauer, L. Applied Clinical Pharmacokinetics, 2nd Ed, McGwaw Hill, 2008.
42. Leucuta, S.E.; Vlase, L. Pharmacokinetics and metabolic drug interactions. Curr. Clin. Pharmacol., 2006, 1: 5-20.
43. Li, S.D.; Huang, L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol. Pharmaceutics, 2008, 5, 496-504.
44. Meibohm, B. Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley, 2006.
45. Nishikawa, M.; Takakura, Y.; Hashida M. Pharmacokinetic evaluation of polymeric carriers. Adv. Drug Deliv. Rev., 1996, 21, 135-155.
46. Mager, D.E. Target-mediated drug disposition and dynamics. Biochem Pharmacol., 2006, 72, 1-10.
47. Amiji, M.M. Nanomedicine for Cancer Therapy. Pharm. Res., 2011, 28, 181-186.
48. Freitas Jr., R.A. "What is nanomedicine?" Nanomed. Nanotechnol. Biol. Med., 2005, 1, 2-9.
49. Kawasaki, E.S.; Player, A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine, 2005, 1, 101-109.
50. Jain, K.K. Nanomedicine: Application of Nanobiotechnology in Medical Practice. Med. Princ. Pract., 2008, 17, 89-101.
51. Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanoparticle delivery of anticancer drugs. Annu. Rev. Med., 2012, 63, 185-198.
52. Caruthers, S.D.; Wickline, S.A.; Lanza, G.M. Nanotechnological applications in medicine. Curr. Opin. Biotechnol., 2007, 18, 26-30.
53. Sinha, R.; Kim, G.J.; Nie, S.; Shin, D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Can. Ther., 2006, 5, 1909-1917.
54. Duncan, R. Polymer conjugates as anti-cancer nanomedicines. Nat. Rev. Cancer., 2006, 6, 688-701.
55. El-Ansary; Al-Daihan, S. On the toxicity of therapeutically used nanoparticles: An overview. J. Toxicol., 2009; doi: 10.1155/2009/754810
56. Couvreur, P.; Vauthier, C. Nanotechnology: Intelligent design to treat complex disease. Pharm. Res., 2006, 23, 1417-1450.
57. Leucuta, S.E. Nanotechnology for delivery of drugs and biomedical applications. Curr. Clin. Pharmacol., 2010, 5, 257-280.
58. Lee, P.Y.; Wong, K.K.Y. Nanomedicine: A new frontier in cancer therapeutics Curr. Drug Deliv., 2011, 8, 245-253.
59. Desai, N. Challenges in development of nanoparticle-based therapeutics. AAPS J, 2012, 14, 282-295.
60. Gupta, A.; Arora, A.; Menakshi, A.; Sehgal, A.; Sehgal, R. Nanotechnology and its applications in drug delivery: a review. WebmedCentral:Int. J. Med. Mol. Med., 2012, 3, WMC002867.
61. Liu, Y.; Miyoshi, H.; Nakamura, M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer, 2007, 120, 2527-2537.
62. Mohanraj, V.J.; Chen, Y. Nanoparticles-A Review. Tropic. J. Pharm. Res., 2006, 5, 561-573.
63. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14, 1310-1316.
64. Torchilin, V. Nanoparticulates as drug carriers, Imperial College Press: London, 2006.
65. Gupta, R.; Kompella, U.B. Nanoparticle technology for drug delivery, Taylor&Francis, 2006.
66. De Villiers, M.M.; Aramvit, P.; Kwon, G.S. Nanotechnology in drug delivery, Springer, 2009.
67. Svenson, S. Carrier-based drug delivery. Am. Chem. Soc., 2004.
68. Sahoo, S.K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today, 2003, 8, 1112-1120.
69. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov., 2003, 2, 347-360.
70. Kwon, G.S. Polymeric drug delivery systems. Taylor&Francis, 2005.
71. Ottenbrite, R.M.; Kim, S.W. Polymeric drugs & drug delivery systems, Technomic Pub., 2000.
72. Uchegbu, I.F.; Schätzlein, A.G. Polymers in Drug Delivery. CRC Taylor&Francis, 2006.
73. Vauthier, C.; Bouchemal, K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res., 2009, 26, 1025-1058.
74. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70, 1-20.
75. Otsuka, H.; Nagasaki, Y.; Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev., 2003, 55, 403-419.
76. Byrne, J.D.; Betancourt, T.; Brannon Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008, 60, 1615-1626.
77. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2004, 56, 1649-1659.
78. Roszek, B.; de Jong, W.H.; Geertsma, R.E. Nanotechnology in medical applications:state-of-the-art in materials and devices. RIVM report 265001001/2005.
79. Sawant, R.R.; Torchilin, V.P. Challenges in development of targeted liposomal therapeutics. AAPS J, 2012, 14, 303-315.
80. Marcato, P.D.; Duran, N. New aspects of nanopharmaceutical delivery systems. J. Nanosci. Nanotechnol., 2008, 8, 1-14.
81. Bibi, S.; Lattmann, E.; Mohammed, A.R.; Perrie Y. Trigger release liposome systems: local and remote controlled delivery? J. Microencapsul., 2012, 29, 262-276.
82. Needham, D. Temperature-sensitive liposome formulation. US20117901709B2, 2011.
83. Svenson, S.; Tomalia, D.A. Dendrimers in biomedical applicationsreflections on the field. Adv. Drug Deliv. Rev., 2005, 57, 2106-2129.
84. Al-Jamal, K.T.; Ramaswamy, C.; Florence, A.T. Supramolecular structures from dendrons and dendrimers. Adv. Drug Deliv. Rev., 2005, 57, 2238-2270.
85. Duncan, R.; Ringsdorf, H.; Satchi Fainaro, R. Polymer therapeutics-polymers as drugs, conjugates and gene delivery systems: past, present and future opportunities. Adv. Polym. Sci., 2006, 192, 1-8.
86. Gaspar, R.; Duncan, R. Polymer carriers: preclinical safety and regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev., 2009, 61, 1220-1231.
87. Lu, Y.; Yang, J.; Sega, E. Issues related to targeted delivery of proteins and peptides. AAPS J, 2006, 8, E466-E478.
88. Wang, J.; Mongayt, D.; Torchilin, V.P. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethyleneglycol)-lipid conjugate and positively charged lipids. J. Drug Target, 2005, 13, 73-80.
89. Duncan, R. Development of HPMA copolymer-anticancer conjugates:clinical experience and lessons learnt. Adv. Drug Deliv. Rev., 2009, 61, 1131-1148.
90. Segal, E.; Satchi-Fainaro, R. Design and development of polymer conjugates as anti-angiogenic agents. Adv. Drug Deliv. Rev., 2009, 61, 1159-1176.
91. Mathiowitz, E.; Chickering, D.E.; Lehr, C.M. Bioadhesive drug delivery systems: Fundamentals, novel approaches and developments. M. Dekker: New York, 1999, pp 76-102.
92. Llabot, J.M.; Salman, H.; Millotti, G.; Bernkop-Schnurch, A.; Allemandi, D.; Irache, J.M. Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan. J. Microencapsulation, 2011, DOI: 10.3109/02652048.2011.576787
93. Preda, M.; Leucuta, S.E. Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization. J. Microencapsulation, 2003, 20, 777-790.
94. Porfire, A.S.; Zabaleta, V.; Gamazo, C.; Leucua, S.E.; Irache, J.M. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles. Int. J. Pharm., 2010, 390, 37-44.
95. Kumar, C. Nanomaterials for Medical Diagnosis and Therapy, Wiley, 2007.
96. Takakura, Y.; Hashida, M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res., 1996, 13, 820-831.
97. Widder, K.J.; Senyei, A.E.; Ranney, D.F. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv. Pharmacol. Chemother., 1977, 16, 213-271.
98. Tomlinson, E. Microsphere delivery systems for drug targeting and controlled release. Int. J. Pharm. Tech. Prod. Mfr., 1983, 4, 49-57.
99. Sharma, D.; Nager, N.; Sing, R.P.; Sharma, A.K. Drug targeting to brain: a review. Int. J. Pharm. Res. Dev., 2011, 3, 34-44.
100. Leucuţa, S.E.; Targeted medecines (in Romanian), Editura Medicalǎ: Bucureşti, 1996, (293 pp).
101. Arvizo, R.R.; Miranda, O.R.; Moyano, D.F.; Walden, C.A.; Giri, K.; et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS ONE, 2011, 6, e24374. doi:10.1371/journal.pone.0024374.
102. Moghimi, S.M.; Davis, S.S. Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection, Crit. Rev. Ther. Drug Carriers Syst., 1994, 11, 31-60.
103. Stolnik, S.; Illum, L.; Davis, S.S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev., 1995, 16, 195-214.
104. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
105. Vasir, J.K.; Reddy, M.K.; Labhasetwar, V. Nanosystems in drug targeting: opportunities and challenges. Curr. Nanosci., 2005; 1, 47-64.
106. Sezaki, H.; Hashida, M. Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst., 1984, 1, 1-38.
107. Allen, T.M.; Hansen, C.B.; Lopes de Menezes, D.E. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev., 1995, 16, 267-284.
108. Gupta, P.K.; Hung, C.T. Quantitative evaluation of targeted drug delivery systems. Int. J. Pharm., 1989, 56, 217-226.
109. Jusko, W.J. Pharmacodynamics of chemotherapeutic effects: dosetime-response relationship for phase-nonspecific agents. J. Pharm. Sci., 1971, 60, 892-895.
110. Suzuki, H.; Nakai, D.; Seita, T.; Sugiyama, Y. Design of a drug delivery system for targeting based on pharmacokinetic consideration. Adv. Drug Deliv. Rev., 1996, 19, 335-357.
111. Ritschel, WA. Handbook of basic pharmacokinetics, 2nd Ed. Drug Intell. Pub.: Hamilton, Ill., 1982.
112. Pyatak, P.; Abuchowski, A. M; Davis, F.F. Preparation of a polyethylene glycol: Superoxide dismutase adduct and an examination of its blood circulation life and anti-inflammatory activity. Res. Commun. Chem. Pathol. Pharmacol., 1980, 29, 113-127.
113. Meijer, D.K.F.; Molema, G. Targeting of drugs to the liver. Semin. Liver Dis., 1995, 15, 202-255.
114. Breitfeld, P.P.; Simmons Jr, C.F.; Strous, G.J.A.M.; Gueze, H.J.; Schwartz, A.L. Cell biology of the asialoglycoprotein receptor system: A model for receptor-mediated endocytosis. Int. Rev. Cytol., 1985, 97, 47-95.
115. Nishikawa, M.; Takakura, Y.; Hashida, M. Pharmacokinetic evaluation of polymeric carriers. Adv. Drug Deliv. Rev., 1996, 21, 135-155.
116. Fujita, T.; Furitsu, H.; Nishikawa, M.; Takakura Y.; Sezaki, H.; Hashida, M. Therapeutic effects of superoxid dismutase derivatives modified with mono and polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochem. Biophys. Res. Commun., 1992, 189, 191-196.
117. Harashima, H.; Kiwada, H. Liposomal targeting and drug delivery: kinetic consideration. Adv. Drug Deliv. Rev., 1996, 19, 425-444.
118. Reza Mozafari, M. Nanocarrier technologies: frontiers of nanotherapy. Springer, 2006.
119. Poznansky, M.; Juliano, R.L. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev., 1984, 36, 277-336.
120. Alving, C.R. Macrophages as targets for delivery of liposomeencapsulated antimicrobial agents. Adv. Drug Deliv. Rev., 1988, 2, 107-128.
121. Achim, M.; Risca, R.; Daicoviciu, D.; Leucuta, S. E. Gelatin microspheres containing epirubicin: pharmaceutical, pharmacokinetic and antitumour effect characterization. STP Pharma Sci., 2002, 12, 275-282.
122. Leucuta, S.E.; Risca R.; Daicoviciu D.; Porutiu D. Albumin microspheres as a drug delivery system for epirubicin: pharmaceutical, pharmacokinetic and biological aspects. Int. J. Pharm., 1988, 41, 213-217.
123. Leucuta, S.E.; Achim, M.; Risca, R.; Postescu, I.D. Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles with epirubicin. S.T.P. Pharm. Sci., 2003, 13, 291-297.
124. Saettone, M. F.; Salminen, L. Ocular inserts for topical delivery. Adv. Drug Deliv. Rev., 1995, 16, 95-106.
125. LeBourlais, C.; Acar, L.; Zia, H.; Sado, P.A.; Needham, T.; Leverge, R. Ophthalmic drug delivery systems-recent advances. Progress Retin. Eye Res., 1998, 17, 33-58.
126. Bourges, J.L.; Gautier, S.E.; Delie, F.; Bejjani, R.A.; Jeanny, J.C.; Gurny, R.; BenEzra, D.; Behar-Cohen, F.F. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Opth. Vis. Sci., 2003, 44, 3562-3569.
127. Leucuta, S.E. The kinetics of in vitro release and pharmacokinetics of miotic response in rabbits of gelatin and albumin microspheres with pilocarpine. Int. J. Pharm., 1988, 41, 213-217.
128. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev., 2001, 46, 169-185.
129. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release, 2001, 74, 47-61.
130. Napper, D.H.; Netchey, A. Studies of the steric stabilization of colloidal particles. J. Colloid Interface Sci., 1971, 37, 528-535.
131. Illum, L.; Davis, S.S. Effect of nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J. Pharm. Sci., 1983, 72, 1086-1090.
132. Fanum, M. Colloids in Drug Delivery. CRC Press, 2010.
133. Gref, R.; Domb, A.; Quellec, P.; Blunk, T.; Müller, R.H.; Verbavatz, J.M.; Langer, R. The controlled intravenous administration of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev., 1995, 16, 215-233.
134. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263,1600-1603.
135. Gabizon, A.; Papahadjopoulos, D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta, 1992, 1103, 94-100.
136. Torchilin, V.P.; Omelyanenko, V.G.; Papisov, M.I.; et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys Acta, 1994, 1195, 11-20.
137. Shaughnessy, J.A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin. Breast Cancer, 2003, 4, 318-328.
138. Allen, T.M.; Hansen, C.B.; de Menenez, D.E.L. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev., 1995, 16, 267-284.
139. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. The AAPS Journal, 2007, 9, E128-E147.
140. Balacescu, O.; Neagoe, I.; Ola, R.; Vlase, L.; Achim, M.; Leucuta, S.E. Doxorubicin pharmacokinetics in organs after administration in mice as free or incapsulated in liposomes (in Rom.) Clujul Medical, 2005, 78, 192-198.
141. Balacescu, O.; Neagoe, I.; Lazar, V.; Kauffmann, A.; Cristea, V.; Ghilezan, N.; Leucuta, S.E. Pharmacogenomic study by microarray technology on the resistence at Cisplatin in ovarian cancer with in vitro and in vivo models (in Romanian). FARMACIA, 2005, 53,118-126.
142. Drummond, D.C.; Meyer, O.; Hong, K.; Kirpotin, D.B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 1999,51, 691-743.
143. Allen, T.M.; Stuart, D.D. Liposomal pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes. In: Janoff AS, editor. Liposomes: rational design. Marcel Dekker, Inc.: New York, 2005, pp. 63-87.
144. Prokop, A. Intracellular delivery. Fundamentals and applications. Springer, 2011.
145. de Fougerolles, A.; Vornlocher, H.P.; Maraganore, J.; Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov., 2007, 6, 443-453.
146. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J, 2007, 9, E128-E147.
147. Utreja, P.; Jain, S.; Tiwary, A.K. Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects. Curr. Drug Deliv., 2010, 7, 152-161.
148. Reza, M.M. Nanocarrier Technologies: Frontiers of Nanotherapy, Springer, 2006.
149. Ríhová, B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev., 1998, 29, 273-289.
150. Sharma, R.; Shrinivas, D. Serum proteomics for cancer: from basic research to clinical application. In: Protein Analysis TechniquesEditors: Rakesh Sharma, Bharati D. Shrinivas, Innovations And Solutions Inc., 2009.
151. Mohanraj, V.J.; Chen, Y. Nanoparticles-a review. Tropic. J. Parm. Res., 2006, 5,561-573.
152. Allen, T.M.; Hansen, C.B.; Lopes de Menezes, D.E. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev., 1995, 16, 267-284.
153. Basile, L.; Pignatello, R.; Passirani, C. Active targeting strategies for anticancer drug nanocarriers. Curr. Drug Deliv. 2012, 9, 255-268.
154. Daugherty, A.L.; Mrsny, R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev., 2006, 58, 686-706.
155. Arruebo, M.; Valladares, M.; Gonzalez-Fernandez, A. Antibodyconjugated nanoparticles for biomedical applications. J. Nanomaterials, 2009, Article ID 439389, 2009, p. 24. doi:10.1155/2009/439389.
156. Kuester and Kloft, In: Pharmacokinetics and pharmacodynamics of biotech drugs, Meibohm (Ed), Wiley, 2006.
157. Leveque D.; Wisniewski, S.; Jehl, F. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res., 2005, 25, 2327-2344.
158. Lobo, E.D.; Hansen R.J. Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2004, 93, 2645-2668.
159. Sun, B.; Ranganathan, B.; Feng, S.S. Multifunctional poly(d, llactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials, 2008, 29, 475-486.
160. Kou, G.; Gao, J.; Wang, H.; Chen, H.; Li, B.; Zhang, D.; Wang, S.; Hou, S.; Qian, W.; Dai, J.; Zhong, Y.; Go, Y. Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J. Biochem. Mol. Biol., 2007, 40, 731-739.
161. Fujita, M.; Lee, B.S.; Khazenzon, N.M. et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(β-L-malic acid). J. Control. Release, 2007, 122, 356-363.
162. Aigner, A. Tumor-targeting nanosystems for the delivery of siRNA. Nanomedicine, 2007, 2, 569-572.
163. Hayes, D.C.; Drummond, D.B.; Kirpotin, et al. Genospheres: selfassembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther., 2006, 13, 646-651.
164. Rajeendran, L.; Knolker, H.J.; Simons K. Subcellular targeting strategies for drug design and delivery. Nat. Rev. Drug Discov., 2010, 9, 29-42.
165. Sheff, D. Endosomes as a route for drug delivery in the real world. Adv. Drug Deliv. Rev., 2004, 56, 927-930.
166. Mohanty, C.; Das, M.; Kanwar, J.R.; Sahoo, S.K. Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr. Drug Delivery, 2011, 8, 45-58.
167. Desai, M.; Pattani, A. Intracellular drug delivery systems: A new paradigm. Express Pharm., 2006, www.expresspharmaonline.com
168. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery, Cell. Mol. Life Sci., 2009, 66, 2873-2896.
169. Pattnaik, G.; Siva Rama Raju, K.; Heeralal, B.; Sajid Ali, M. Nanovehicles: an efficient carrier for active molecules for entry into the cell. Int. J. Pharm. Sci. Rev. Res., 2010, 4, 15-21.
170. Lenaerts, V.; Nagelkerke, J.F.; Van, B.T.J.; Couvreur, P.; Grislain, L.; Roland, M.; Speiser, P. In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells. J. Pharm. Sci., 1984, 73, 980-982.
171. Sahay, G.; Alakhova, D.; Kabanov, A.V. Endocytosis of nanomedicines. J. Control. Release, 2010, 145, 182-195.
172. Prokop, A. Intracellular delivery. Fundamentals and applications, Springer, 2011.
173. de Fougerolles, A.; Vornlocher, H.P.; Maraganore, J.; Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov., 2007, 6, 443-453.
174. Elsabahy, M.; Nazarali, A.; Foldvari, M. Non-Viral Nucleic acid delivery: key challenges and future directions. Curr. Drug Deliv., 2011, 8, 235-244.
175. Jeong, J.H.; Park, T.G.; Kim, S.H. Self-asembled and nanostructured siRNA delivery systems. Pharm. Res., 2011, 28, 2072-2085.
176. Lu, P. Therapeutic Delivery of RNAi. In: Rossi, J. (ed.), RNA Interference: Principles and Applications, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London, 2007, http://hstalks.com/bio
177. Corey, D.R. Chemical modification: the key to clinical application of RNA interference? J. Clin. Invest., 2007, 117, 3615-3622.
178. Musacchio, T.; Navarro, G.; Torchilin, V.P. Molecular assemblies for siRNA delivery. J. Drug Deliv. Sci. Tech., 2012, 22, 5-16.
179. Oh, Y.K.; Park, T.G. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev., 2009, 1, 850-862.
180. Wagner, R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature, 1994, 372, 333-335.
181. Novina, C.D.; Sharp, P.A. The RNAi revolution. Nature, 2004, 430, 161-164.
182. Dorsett, Y.; Tuschl, T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov., 2004, 3, 318-329.
183. Beilvert, F.; Mevel, M.; Chatin, B.; Pitard, B. Local siRNA delivery by non-viral vectors. J. Drug Del. Sci. Tech., 2012, 22, 17-27.
184. Nascimento, T.L.; Hillaireau. H.; Fattal E. Nanoscale particles for lung delivery of siRNA. J. Drug Deliv. Sci. Tech., 2012, 22, 99-108.
185. Cejka, D.; Losert, D.; Wacheck, V. Short interfering RNA (siRNA): tool or therapeutic? Clin. Sci., 2006, 110, 47-58.
186. Underwood, L. siRNA gene silencing for therapeutic purposes. Basic Biotechnology, 2010, 6, 59-64.
187. Wang, J.; Lu, Z.; Guillaume Wientjes, M.; Au, J.L.S. Delivery of sirna therapeutics: barriers and carriers. The AAPS Journal, 2010, 12, 492-503.
188. Yu, B. Oligonucleotide based liposomal nanoparticles for leukemia and liver cancer therapy. Thesis, Ohio Statwe University, 2010.
189. Dykxhoorn, D.M.; Palliser, D.; Lieberman, J. The silent treatment: siRNAs as small molecule drugs. Gene Ther., 2006, 13, 541-552.
190. Yu, B.; Zhao, X.; Lee, L.J.; Lee, R.J. Targeted delivery systems for oligonucleotide therapeutics. AAPS J, 2009, 11, 195-203.
191. Behlke, M.A. Progress towards in vivo use of siRNAs. Mol. Ther., 2006, 13, 644-670.
192. Juliano, R.; Alam, M.R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 2008, 36, 4158-4171.
193. Kim, E.J.; Park, T.G.; Oh, Y.K.; Shim, C.K. Assessment of siRNA pharmacokinetics using ELISA-based quantification. J. Control. Release, 2010, 143, 80-87.
194. Leserman, L.D.; Weinstein, J.N.; Blumenthal, R.; Terry, W.D. Receptor-mediated endocytosis of antibodyopsonized liposomes by tumor cells. Proc. Natl. Acad. Sci. U.S.A., 1980, 77, 4089-4093.
195. Mastrobattista, E. Targeted liposomes for cytosolic drug delivery to tumor cells. Thesis, Utrecht University, 2001.
196. Palakurthi, S.; Yellepeddi, V.K.; Kumar, A. Nanocarriers for cytosolic drug and gene delivery in cancer therapy. In: Biomedical Engineering, Trends, Research and Technologies, Malgorzata Anna Komorowska, Sylwia Olsztynska-Janus (Eds), InTech, 2011, Chp. 11, 245-272.
197. Li, S.D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharmaceutics.08/2008; DOI: 10.1021/mp800049w
198. Li, Y.; Wei, P.; Li, J.; Li, L. Pharmacokinetic analysis and optimization of hydroxycamptothecin-loaded nanoparticles for liver targeting. Drug Dev. Ind. Pharm., 11/2011; DOI: 10.3109/03639045.2011.630393.
199. Ali, M.M.; Yoo, B.; Pagel, M.D. Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol. Pharm., 2009, 6, 1409-1416.
200. Li, M.; Al-Jamal, K.T.; Kostarelos, K.; Reineke, J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano, 2010, 4, 6303-6317.
201. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm., 2008, 5, 505-515.
202. Kaiser, C.R.; Flenniken, M.L.; Gillitzer, E.; Harmsen, E.; Harmsen, A.G.; Jutila, M.A.; Douglas, T.; Young, M.J. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int. J. Nanomedicine, 2007, 29, 715-733.
203. Owens, D.E.; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307, 93-102.
204. Arvizo, R.R.; Miranda, O.R.; Moyano, D.F.; et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS ONE, 2011, 6, e24374. DOI: 10.1371/journal.pone.0024374
205. Liu, M.; Li, H.; Luo, G.; Liu, Q.; Wang, Y. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Arch. Pharmacal Res., 2008, 31, 547-554.
206. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 2010, 31, 3657-3666.
207. Li, S.D.; Huang, L. Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2009, 1788, 2259-2266.
208. Farokhzad, O.C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano, 2009, 3, 16-20.
209. Sui, M.; Liu, W.; Shen, Y. Nuclear drug delivery for cancer chemotherapy. J. Control. Release, 2011, 155, 227-236.
210. Rout, M.P.; Aitchinson, J.D. The nuclear pore complex as a transport machine. J. Biol. Chem., 2001, 276, 16593-16596.
211. Boeckle, S.; Wagner, E.; Ogris, M. Transmembrane targeting of DNA with membrane active peptides. In: Biomedical aspects of drug targeting, Muzykantov V.R.; Torchilin, V.P. Eds., Kluwer Academic Pub., 2002.
212. De Coupade, C.; Fittipaldi, A.; Chagnas, V.; Michel, M.; Carlier, S.; Tasciotti, E.; Darmon, A.; Ravel, D.; Kearsey, J.; Giacca, M.; Cailler, F. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem. J., 2005, 390, 407-418.
213. Veerle, K.; Cornelissen, B. Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy. Pharmaceuticals, 2010, 3, 600-620.
214. Munyendo, W.L.L.; Lv, H.; Benza-Ingoula, H.; Baraza, L.D.; Zhou, J. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules, 2012, 2, 187-202.
215. Trabulo, S.; Cardoso, A.L.; Mano, M.; de Lima, M.C.P. Cellpenetrating peptides-Mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals, 2010, 3, 961-993.
216. Christophe, D.; Christophe-Hobertus, C.; Pichin, B. Nuclear targeting of proteins: how many different signals? Cell. Signall., 2000, 12, 337-341.
217. Chahine, M.N.; Pierce, G.N. Therapeutic targeting of nuclear protein import in pathological cell conditions. Pharmacol. Rev., 2009, 61, 358-372.
218. Ochiai, H.; Harashima, H.; Kamiya, H. Intranuclear disposition of exogenous DNA in vivo: Silencing, methylation and fragmentation. FEBS Lett., 2006, 580, 918-922.
219. Zanta, M.A.; Belguise-Valladier, P.; Behr, J.P. Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc. Nat. Acad. Sci. USA, 1999, 96, 91-96, doi: 10.1073/pnas.96.1.91
220. Birbach, A.; Bailey, S.T.; Ghosh, S.; Schmid, J.A. Cytosolic, nuclear and nucleolar localization signals determine subcellular distribution and activity of the NF-βB inducing kinase NIK. J. Cell. Sci., 2004, 117, 3615-3624.
221. Kalderon, D.; Roberts, B.L.; Richardson, W.D.; Smith, A.E. Short amino acid sequence able to specify nuclear location. Cell, 1984, 39, 499-509.
222. Jeon, O.; Won Lim, H.; Lee, M.; Song, S.J.; Kim, B.S. Poly(llactide-co-glycolide) nanospheres conjugated with a nuclear localization signal for delivery of plasmid DNA. J. Drug Targeting, 2007, 15, 190-198.
223. Gad, S.C.; Ed. Handbook of pharmaceutical biotechnology. Wiley: New York, 2007.
224. Ledley, T.S.; Ledley, F.D. Multicompartimental, numerical-model of cellular events in the pharmacokinetics of gene therapies. Hum. Gene Ther., 1994, 5, 679-691.
225. Gene Therapy and Emerging Molecular Therapies. Chp.5, 49-56. www.medicaltextbooksrevealed.com/files/16654-53.pdf
226. Nishikawa, M.; Takakura, Y.; Hashida, M. Theorical considerations involving the pharmacokinetics of plasmid DNA. Adv. Drug Deliver. Rev., 2005, 57, 675-88.
227. Nishikawa, M.; Takakura, Y.; Hashida, M. Pharmacokinetic considerations regarding non-viral cancer gene therapy. Cancer Sci., 2008, 99, 856-62.
228. Yu, L.; Suh, H.; Koh, J.J.; Kim, S.W. Systemic administration of TerplexDNA system: pharmacokinetics and gene expression. Pharm. Res., 2001, 18, 1277-1283.
229. Parra-Guillen, Z.P.; Gonzalez-Aseguinolaza, G.; Beraondo, P.; Troconiz, I.F. Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview. Pharm. Res., 2010, 27, 1487-1497.
230. Nomura, T.; Nakajim, S.; Kawabata, K.; Yamashita, F.; Takakura, Y.; Hashida, M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res., 1997, 57, 2681-6.
231. Mok, W.; Stylianopoulos, T.; Boucher, Y.; Jain, R.K. Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin. Cancer Res., 2009, 15, 2352-60.
232. Vasir, J.K.; Labhasetwar, V. Nanoparticles for gene delivery:Formulation Characteristics. In: Nanoparticulate drug delivery systems, Deepak Thassu, Michel Deleers. Yashwant Pathak (Eds), Informa Healthcare: NY, 2006, chp.18.
233. Kamiya, H.; Tsuchiya, H.; Yamazaki, J.; Harashima, H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv. Drug Deliver. Rev., 2001, 52, 153-64.
234. Kamiya, H.; Akita, H.; Harashima, H. Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discov. Today, 2003, 8, 990-996.
235. Moriguchi, R.; Kogure, K.; Harashima, H. Non-linear pharmacodynamics in the transfection efficiency of a non-viral gene delivery system. Int. J. Pharm., 2008, 363,192-198.
236. Yamada, Y.; Kamiya, H.; Harashima, H. Kinetic analysis of protein production after DNA transfection. Int. J. Pharm., 2005, 299, 34-40.
237. Taira, K.; Kataoka, K.; Niidome, T. Eds. Non-viral Gene Therapy. Gene Design and Delivery. Springer, 2005.
238. Akita, H.; Khalil, I.A.; Kogure, K.; Harashima, H. Pharmacokinetics of gene delivery in cells. In: Taira, K.; Kataoka, K.; Niidome, T (Eds). Non-viral Gene Therapy. Gene Design and Delivery. Springer, 2005, p.135.
239. Simonson, O.E.; Svahn, M.G.; Törnquist, E.; Lundin, K.E.; Smith, C.I. Bioplex technology: novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids. Curr. Pharm. Des., 2005, 11, 3671-3680.
240. Viola, J.R.; El-Andaloussi, S.; Oprea, I.I.; Edvard Smith, C.I. Nnanovectors for gene delivery: factors that govern successful therapeutics. Expert Opin. Drug Deliv., 2010, 7, 721-735.
241. Branden, L. J.; Christensson, B.; Smith, C. I. Methods Enzymol. In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides. Gene Ther., 2001, 8, 84-87.
242. Branden, L. J.; Mohamed, A. J.; Smith, C. I. A peptide nucleic acid nuclear localization signal fusion that mediates nuclear transport of DNA. Nat. Biotechnol., 1999, 17, 784-787.
243. Oprea, I.I.; Simonson, O.E.; Moreno, P.M.; Viola, J.R.; Lundin, K.E.; Smith, C.I.E. Temperature-assisted cyclic hybridization (TACH): an improved method for hybridization. Mol. Biotechnol., 2010, 45, 171-179.
244. Lundin, K.E.; Simonson, O.E.; Moreno, P.M.D.; Zaghloul, E.M.; Oprea, I.I.; Svahn, M.G.; Edvard, S. C.I. Nanotechnology approaches for gene transfer. Genetica, 2009, 137, 47-56.
245. Zaghloul, E.M.; Madsen, A.S.; Moreno, P.M.D.; Oprea, I.I.; El-Andaloussi, S.; Bestas, B.; Gupta, P.; Pedersen, E.B.; Lundin, K.E.; Wengel, J.; Smith, C.I.E. Optimizing anti-gene oligonucleotide 'Zorro-LNA' for improved strand invasion into duplex DNA. Nucleic Acids Res., 2011, 39, 1142-1154.
246. Oprea, I.I. Gene therapy: new developments of non-viral vectors. Thesis, University of Medicine and Pharmacy, Cluj-Napoca, 2010 (Supervisors: Leucuta, S.E.; Smith, C.I.).